FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
DROIA is a hands-on investment company, focused on developing cancer therapies. DROIA has a close relationship with ACF, a not-for-profit organization. We are therefore extremely dedicated to the fight against cancer, all while creating shareholder value.
DROIA was founded in 2011 and has to day made 5 investments. We are data driven and invest in breakthrough potential. Our investments can be early stage but with a clear road to clinical development; several of our companies are clinical stage.
DROIA is a venture investor, exclusively focused on the development of oncology therapies. We are dedicated to making a difference in the fight against cancer. We have adopted a unique investment model to accelerate development in our portfolio companies, the DROIACs. We aim to bring promising therapies to patients faster, creating both patient benefit and shareholder value. Hence our name: Double Return On Investment, Accelerated: DROIA.
DROIA was established in 2011. The holding is funded by European private investors, and operates from offices in Luxemburg and Brussels. We invest worldwide.
DROIA makes select investments in early stage drug development companies with solid preclinical proof of concept. Our investment decisions are based on breakthrough potential as evidenced by strong research data. Our participations today include companies in immune-oncology and tumor metabolism; however we welcome any technology with great promise and constantly analyze new discoveries.
DROIA invests by participating in companies or by creating new ventures around promising technology. We want to support our companies at least up to clinical proof of concept, yet we have no deadlines to exit, in case remaining with a company can benefit further development of its therapies.
DROIA is a hands-on investor and actively participates in the development of the DROIACs and their therapies. We have an in-house expert team with experience in clinical oncology, drug development and entrepreneurship. We help the DROIACS by providing not just financial means, but also people and assistance on scientific, preclinical, clinical & CMC development, on IP & regulatory, on licensing, finance & transactions, on company building.
Our network of oncology leaders gives us access to top-level institutions and KOL’s around the world and allows our companies to benefit from a global knowledge base.
We firmly believe that our approach can improve and accelerate the development of the cancer therapies that will come out of today’s many exciting scientific findings.